We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$17.7M
Cap. Flow
+$78.3M
Cap. Flow %
7.08%
Top 10 Hldgs %
56.11%
Holding
90
New
21
Increased
23
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
PFE icon
Pfizer
PFE
+$15.7M
3
UTHR icon
United Therapeutics
UTHR
+$15.6M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.3M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$22.8M
2
NVO
Novo Nordisk
NVO
+$16.5M
3
HRTX icon
Heron Therapeutics
HRTX
+$9.45M
4
INCY icon
Incyte
INCY
+$5.91M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Miscellaneous 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALA
51
DELISTED
Calithera Biosciences, Inc
CALA
$2.98M 0.27%
48,243
+21,751
+82% +$1.74M
ARQL
52
DELISTED
Arqule Inc
ARQL
$2.82M 0.26%
393,387
+111,530
+40% +$1.05M
QTTB icon
53
Q32 Bio
QTTB
$332M
$2.65M 0.24%
+8,128
New +$2.76M
CYTK icon
54
Cytokinetics
CYTK
$10.3B
$2.4M 0.22%
+210,992
New +$2.65M
MRTX
55
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.4M 0.22%
+30,800
New +$2.89M
ACRS icon
56
Aclaris Therapeutics
ACRS
$818M
$2.06M 0.19%
1,911,573
– –
HRTX icon
57
Heron Therapeutics
HRTX
$63.2M
$1.92M 0.17%
103,602
-513,583
-83% -$9.45M
KALA icon
58
KALA BIO
KALA
$10.8M
$1.82M 0.16%
191
+72
+61% +$876K
SNDX icon
59
Syndax Pharmaceuticals
SNDX
$1.77B
$1.82M 0.16%
243,150
+421
+0.2% +$3.83K
ALGN icon
60
Align Technology
ALGN
$10.9B
$1.81M 0.16%
+10,000
New +$2.08M
PTLA
61
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.59M 0.14%
+59,191
New +$1.66M
APLT
62
DELISTED
Applied Therapeutics
APLT
$1.56M 0.14%
142,004
– –
SNDX icon
63
PUT
Syndax Pharmaceuticals
SNDX
$1.77B
$1.49M 0.14%
+200,000
New +$1.82M
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.25B
$1.48M 0.13%
516,734
+90,334
+21% +$281K
SVRA icon
65
Savara
SVRA
$1.11B
$1.4M 0.13%
+527,318
New +$1.32M
SYBX
66
DELISTED
Synlogic
SYBX
$1.32M 0.12%
38,331
– –
APLS
67
DELISTED
Apellis Pharmaceuticals
APLS
$1.19M 0.11%
49,580
– –
VIRX
68
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$816K 0.07%
+32,398
New +$935K
SNDX icon
69
CALL
Syndax Pharmaceuticals
SNDX
$1.77B
$746K 0.07%
+100,000
New +$911K
PDSB icon
70
PDS Biotechnology
PDSB
$16.4M
$482K 0.04%
142,635
– –
ABBV icon
71
AbbVie
ABBV
$443B
– –
-28,911
Closed -$2.1M
ACAD icon
72
Acadia Pharmaceuticals
ACAD
$4.77B
– –
-155,576
Closed -$4.16M
ADVM
73
DELISTED
Adverum Biotechnologies
ADVM
– –
-18,706
Closed -$2.23M
ALNY icon
74
Alnylam Pharmaceuticals
ALNY
$34.5B
– –
-27,792
Closed -$2.02M
AMGN icon
75
PUT
Amgen
AMGN
$212B
– –
-50,000
Closed -$9.21M
1 2
3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Sofinnova Investments held 90 positions worth $1.11B, up 1.6% from $1.09B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sofinnova Investments deployed $78.3M of net new capital in Q3 2019, opening 21 new positions and adding to 23 existing holdings. Its largest new stake was Amgen: 92,300 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $22.8M trimmed.

  • Sofinnova Investments's largest Q3 2019 buy was Amgen: 92,300 shares worth $17.9M.
  • Sofinnova Investments added most to Bristol-Myers Squibb in Q3 2019, an estimated $14.3M increase.
  • Sofinnova Investments's biggest Q3 2019 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $22.8M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2019, selling an estimated $16.5M.
  • Sofinnova Investments's ten largest holdings make up 56% of its $1.11B portfolio in Q3 2019.
  • Sofinnova Investments opened 21 new positions and closed 19 in Q3 2019.
  • Sofinnova Investments's portfolio value rose 1.6% quarter-over-quarter to $1.11B.

Based on Sofinnova Investments's 13F filing for Q3 2019, filed 14 Nov 2019.